86 results on '"Cecchin, Diego"'
Search Results
2. EANM perspectives for CZT SPECT in brain applications.
- Author
-
Verger, Antoine, Cecchin, Diego, Guedj, Eric, Albert, Nathalie L, Brendel, Matthias, Fraioli, Francesco, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Yakushev, Igor, Van Weehaeghe, Donatienne, Fernandez, Pablo Aguiar, Garibotto, Valentina, and Imbert, Laetitia
- Published
- 2024
- Full Text
- View/download PDF
3. Cutting-Edge Strategies for Renal Tumour-like Lesions in Granulomatosis with Polyangiitis: A Systematic Review.
- Author
-
Iorio, Luca, Pizzi, Marco, Cecchin, Diego, Davanzo, Federica, Ghirardello, Anna, Dei Tos, Angelo Paolo, Doria, Andrea, and Padoan, Roberto
- Subjects
- *
ANTINEUTROPHIL cytoplasmic antibodies , *IMMUNOSUPPRESSIVE agents , *RENAL biopsy , *VASCULITIS , *GRANULOMA , *MUCOCUTANEOUS lymph node syndrome , *GRANULOMATOSIS with polyangiitis - Abstract
Background: Granulomatosis with polyangiitis (GPA) is characterised by granulomatous inflammation and small-to-medium vessel necrotising vasculitis, mainly affecting respiratory tract and kidneys. Renal involvement presenting as tumour-like lesions poses diagnostic and treatment challenges. Methods: Following the observation of a GPA patient presenting with multiple renal tumour-like lesions, we conducted a systematic literature review on MEDLINE/PubMed, EMBASE, and Cochrane databases. Data gathered from the literature were analysed to summarise the diagnostic approach, management, and outcome of renal GPA-related tumour-like lesions. Results: a 49-year-old female presented with persistent constitutional symptoms and multiple bilateral renal lesions. Renal biopsy showed chronic interstitial inflammation with necrotising granulomas. Laboratory tests disclosed positive anti-proteinase 3 (PR3) anti-neutrophil cytoplasmic antibody (ANCA) leading to a final diagnosis of GPA. She was effectively treated with high-dose glucocorticoids and rituximab. Literature search yielded 41 articles, concerning 42 GPA patients with renal masses, presenting bilaterally in 23.8% of the cases. Positive PR3-ANCA was observed in 86.5% of the cases. Half of 42 patients showed kidney abnormalities. Treatment with glucocorticoids (83.3%) and immunosuppressive agents (80.9%) resulted in an overall good remission rate and favourable prognosis. Conclusions: GPA should be considered in the differential diagnoses of kidney tumour-like lesions. The diagnosis is challenging, and histological examination greatly contributes to the diagnostic work-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. 18F-Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Monitoring of Brain Metabolic Changes in a Case of Arteriovenous Malformation–Related Steal Phenomenon Symptoms.
- Author
-
Anglani, Mariagiulia, Cecchin, Diego, Cester, Giacomo, Simonato, Davide, Baracchini, Claudio, Della Puppa, Alessandro, and Causin, Francesco
- Subjects
- *
POSITRON emission , *CEREBRAL arteriovenous malformations , *DIGITAL subtraction angiography , *RESONANCE , *MAGNETIC resonance imaging , *STEREOTACTIC radiosurgery - Abstract
Unruptured brain arteriovenous malformations (AVMs) represent a complex disease in young healthy adults. Most often AVMs are clinically silent but also can display a neurologic syndrome due to hypoperfusion/hypometabolism in perilesional brain tissue called steal phenomenon. A 34-year-old woman was admitted to a secondary neurologic center complaining of a right hemiparesis and secondarily generalized seizures. Computed tomography scan and magnetic resonance imaging of the brain showed a left prerolandic AVM without signs of acute or previous bleedings. Digital subtraction angiography confirmed a left juxta-central AVM, with a diffuse pattern, fed by hypertrophic rolandic branches from the left middle cerebral artery. An 18F-fluorodeoxyglucose positron emission tomography-magnetic resonance imaging scan was performed 3 days after the critical episode. A significant hypometabolism in parenchymal regions ipsilaterally to the AVM was detected. Two embolization sessions were performed by means of N-butyl cyanoacrylate glue. At the end of the second procedure, a decrease of the shunt-flow and AVM size was observed. Six months later, 18F-fluorodeoxyglucose positron emission tomography-magnetic resonance imaging scan showed persistent hypometabolism located in the AVM area, with a significant improvement of the cortical hemispheric hypometabolism. The patient was asymptomatic and was sent to stereotactic radiosurgery to complete the treatment. In clinical practice, irritative symptoms in patients with unruptured AVMs could lead to erroneous evaluations. In case of fluctuating clinical syndromes, like our case, establishing that symptoms are related to a steal phenomenon is usually difficult. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. A new integrated dual time-point amyloid PET/MRI data analysis method.
- Author
-
Cecchin, Diego, Barthel, Henryk, Poggiali, Davide, Cagnin, Annachiara, Tiepolt, Solveig, Zucchetta, Pietro, Turco, Paolo, Gallo, Paolo, Frigo, Anna Chiara, Sabri, Osama, and Bui, Franco
- Published
- 2017
- Full Text
- View/download PDF
6. Parkinson-like features in ALS with predominant upper motor neuron involvement.
- Author
-
D'Ascenzo, Carla, Cecchin, Diego, Santelli, Luca, Palmieri, Arianna, Gaiani, Alessandra, Querin, Giorgia, Cima, Valentina, Volpe, Marco, Bello, Luca, Bui, Franco, Cagnin, Annachiara, Angelini, Corrado, Pegoraro, Elena, and Sorarù, Gianni
- Subjects
- *
PARKINSONIAN disorders , *MOTOR neuron diseases , *POSITRON emission tomography , *AMYOTROPHIC lateral sclerosis , *SINGLE-photon emission computed tomography , *UBIQUITIN , *DIAGNOSIS - Abstract
Owing to the frequent observation of poverty of movements, facial hypomimia and balance impairment, amyotrophic lateral sclerosis (ALS) variant with predominance of upper motor neuron involvement (UMN-ALS) is prone to be diagnosed with Parkinsonism. A clinical assessment, including the velocity-dependent stretch response test to differentiate between pyramidal and extrapyramidal stiffness; the Unified Parkinson's Disease Rating Scale and the Berg Balance Scale to assess degree of bradykinesia and postural instability; and 123I-FP-CIT scintigraphy evaluation to investigate the nigrostriatal circuit involvement, were carried out to characterize Parkinson-like features in UMN-ALS patients. Sixteen UMN-ALS patients were included in the study. The velocity-dependent stretch response indicated spasticity in all the muscles tested. The degree of stiffness was found to be related to bradykinesia and postural instability. Eleven patients (70%) showed a reduction in striatal 123I-FP-CIT uptake found to be related to disease duration and patients' ages but not to scores of the functional scales. Slowness of movements and postural instability noted in our patients could be mostly attributed to spasticity. The lack of any correlation between UPDRS or BBS scores and the degree of nigrostriatal impairment on DaTSCAN seems to disprove nigrostriatal circuit involvement in these extrapyramidal-like features. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Multimodal neuroimaging in a child with sporadic hemiplegic migraine: A contribution to understanding pathogenesis.
- Author
-
Toldo, Irene, Cecchin, Diego, Sartori, Stefano, Calderone, Milena, Mardari, Rodica, Cattelan, Francesca, Laverda, Anna Maria, Drigo, Paola, and Battistella, Pier Antonio
- Subjects
- *
MIGRAINE , *JUVENILE diseases , *HEMIPLEGIA , *CREATININE , *APHASIA - Abstract
Background: Hemiplegic migraine (HM) is a rare variety of migraine with aura, characterized by motor deficits during the aura, often beginning in childhood. The hemiplegic attacks can be severe and prolonged but the prognosis is usually good. Data on neuroimaging, including diffusion-weighted imaging (DWI) and spectroscopy, during prolonged attacks of HM are quite limited, particularly in children.Case: An eight-year-old female had a prolonged attack of sporadic HM characterized by right-sided hemiplegia, global aphasia, fever and impairment of consciousness. MRI nine hours after hemiplegia onset was negative, while the following MRI scans (days 4 and 11) documented a progressive increase in cortical swelling in the left hemisphere with mild hyperintensity on DWI and mild reduction of apparent diffusion coefficient values. Proton MRI spectroscopy (MRS) (day 15) showed a decrease in the N-acetylaspartate/creatine ratio in the left hemisphere. 99mTc-ECD single-photon emission tomography (SPET) (day 27) showed marked left hemispheric hypoperfusion. The patient recovered completely after 40 days and neuroimaging follow-up (MRI and SPET) after six months was normal. The patient carried a missense mutation of the ATP1A2 gene.Conclusion: Multimodal neuroimaging (MRI, DWI, MRS, SPET) in a prolonged HM attack supports evidence for a primary neuronal dysfunction. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
8. The functional role of cerebellum in visual hallucinations.
- Author
-
Zorzi, Giovanni, Cecchin, Diego, Poggiali, Davide, Corbetta, Maurizio, and Cagnin, Annachiara
- Subjects
- *
CEREBELLUM , *HALLUCINATIONS - Published
- 2021
- Full Text
- View/download PDF
9. Oversampling Errors in Multimodal Medical Imaging Are Due to the Gibbs Effect.
- Author
-
Poggiali, Davide, Cecchin, Diego, Campi, Cristina, and De Marchi, Stefano
- Subjects
- *
MEDICAL errors , *DIAGNOSTIC imaging , *THREE-dimensional imaging , *SAMPLING errors , *SOFTWARE development tools , *GIBBS sampling , *INTERPOLATION - Abstract
To analyze multimodal three-dimensional medical images, interpolation is required for resampling which—unavoidably—introduces an interpolation error. In this work we describe the interpolation method used for imaging and neuroimaging and we characterize the Gibbs effect occurring when using such methods. In the experimental section we consider three segmented three-dimensional images resampled with three different neuroimaging software tools for comparing undersampling and oversampling strategies and to identify where the oversampling error lies. The experimental results indicate that undersampling to the lowest image size is advantageous in terms of mean value per segment errors and that the oversampling error is larger where the gradient is steeper, showing a Gibbs effect. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Performance evaluation of the 3D-ring cadmium–zinc–telluride (CZT) StarGuide system according to the NEMA NU 1-2018 standard.
- Author
-
Zorz, Alessandra, Rossato, Marco Andrea, Turco, Paolo, Colombo Gomez, Luca Maria, Bettinelli, Andrea, De Monte, Francesca, Paiusco, Marta, Zucchetta, Pietro, and Cecchin, Diego
- Subjects
- *
COLLIMATORS , *SEMICONDUCTOR detectors , *SPATIAL systems , *SPATIAL resolution , *SINGLE-photon emission computed tomography , *NUCLEAR medicine , *SCINTILLATORS - Abstract
Background: The application of semi-conductor detectors such as cadmium–zinc–telluride (CZT) in nuclear medicine improves extrinsic energy resolution and count sensitivity due to the direct conversion of gamma photons into electric signals. A 3D-ring pixelated CZT system named StarGuide was recently developed and implemented by GE HealthCare for SPECT acquisition. The system consists of 12 detector columns with seven modules of 16 × 16 CZT pixelated crystals, each with an integrated parallel-hole tungsten collimator. The axial coverage is 27.5 cm. The detector thickness is 7.25 mm, which allows acquisitions in the energy range [40–279] keV. Since there is currently no performance characterization specific to 3D-ring CZT SPECT systems, the National Electrical Manufacturers Association (NEMA) NU 1-2018 clinical standard can be tailored to these cameras. The aim of this study was to evaluate the performance of the SPECT/CT StarGuide system according to the NEMA NU 1-2018 clinical standard specifically adapted to characterize the new 3D-ring CZT. Results: Due to the integrated collimator, the system geometry and the pixelated nature of the detector, some NEMA tests have been adapted to the features of the system. The extrinsic measured energy resolution was about 5–6% for the tested isotopes (99mTc, 123I and 57Co); the maximum count rate was 760 kcps and the observed count rate at 20% loss was 917 kcps. The system spatial resolution in air extrapolated at 10 cm with 99mTc was 7.2 mm, while the SPECT spatial resolutions with scatter were 4.2, 3.7 and 3.6 mm in a central, radial and tangential direction respectively. Single head sensitivity value for 99mTc was 97 cps/MBq; with 12 detector columns, the system volumetric sensitivity reached 520 kcps MBq−1 cc−1. Conclusions: The performance tests of the StarGuide can be performed according to the NEMA NU 1-2018 standard with some adaptations. The system has shown promising results, particularly in terms of energy resolution, spatial resolution and volumetric sensitivity, potentially leading to higher quality clinical images. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.
- Author
-
Van Weehaeghe, Donatienne, Lapauw, Bruno, Fraioli, Francesco, Cecchin, Diego, Verger, Antoine, Guedj, Eric, Albert, Nathalie L, Brendel, Matthias, Yakushev, Igor, Barthel, Henryk, Traub-Weidinger, Tatjana, Tolboom, Nelleke, and Giessen, Elsmarieke Van De
- Subjects
- *
POSITRON emission tomography , *NEUROENDOCRINE tumors , *PITUITARY gland , *CORTICOTROPIN releasing hormone , *CUSHING'S syndrome , *GRAVES' disease - Abstract
The article discusses the use of positron emission tomography (PET) in the diagnosis and management of functional pituitary neuroendocrine tumors (PitNETs). PitNETs are common intracranial tumors that can cause significant health issues. While magnetic resonance imaging (MRI) is the primary diagnostic method, it has limitations in detecting certain types of PitNETs. PET imaging with radiolabeled amino acids, such as [11C]MET and [18F]FET, shows promise in accurately detecting and localizing functional PitNETs. However, further research and larger studies are needed to determine the accuracy and clinical indications of PET imaging in this context. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
12. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy.
- Author
-
Traub-Weidinger, Tatjana, Arbizu, Javier, Barthel, Henryk, Boellaard, Ronald, Borgwardt, Lise, Brendel, Matthias, Cecchin, Diego, Chassoux, Francine, Fraioli, Francesco, Garibotto, Valentina, Guedj, Eric, Hammers, Alexander, Law, Ian, Morbelli, Silvia, Tolboom, Nelleke, Van Weehaeghe, Donatienne, Verger, Antoine, Van Paesschen, Wim, von Oertzen, Tim J., and Zucchetta, Pietro
- Subjects
- *
SINGLE-photon emission computed tomography , *PEOPLE with epilepsy , *MEDICAL personnel , *FUNCTIONAL magnetic resonance imaging , *POSITRON emission tomography , *PARTIAL epilepsy - Abstract
Epilepsy is one of the most frequent neurological conditions with an estimated prevalence of more than 50 million people worldwide and an annual incidence of two million. Although pharmacotherapy with anti-seizure medication (ASM) is the treatment of choice, ~30% of patients with epilepsy do not respond to ASM and become drug resistant. Focal epilepsy is the most frequent form of epilepsy. In patients with drug-resistant focal epilepsy, epilepsy surgery is a treatment option depending on the localisation of the seizure focus for seizure relief or seizure freedom with consecutive improvement in quality of life. Beside examinations such as scalp video/electroencephalography (EEG) telemetry, structural, and functional magnetic resonance imaging (MRI), which are primary standard tools for the diagnostic work-up and therapy management of epilepsy patients, molecular neuroimaging using different radiopharmaceuticals with single-photon emission computed tomography (SPECT) and positron emission tomography (PET) influences and impacts on therapy decisions. To date, there are no literature-based praxis recommendations for the use of Nuclear Medicine (NM) imaging procedures in epilepsy. The aims of these guidelines are to assist in understanding the role and challenges of radiotracer imaging for epilepsy; to provide practical information for performing different molecular imaging procedures for epilepsy; and to provide an algorithm for selecting the most appropriate imaging procedures in specific clinical situations based on current literature. These guidelines are written and authorized by the European Association of Nuclear Medicine (EANM) to promote optimal epilepsy imaging, especially in the presurgical setting in children, adolescents, and adults with focal epilepsy. They will assist NM healthcare professionals and also specialists such as Neurologists, Neurophysiologists, Neurosurgeons, Psychiatrists, Psychologists, and others involved in epilepsy management in the detection and interpretation of epileptic seizure onset zone (SOZ) for further treatment decision. The information provided should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals and imaging modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Data-driven analysis of regional brain metabolism in behavioral frontotemporal dementia and late-onset primary psychiatric diseases with frontal lobe syndrome: A PET/MRI study.
- Author
-
Cagnin, Annachiara, Pigato, Giorgio, Pettenuzzo, Ilaria, Zorzi, Giovanni, Roiter, Beatrice, Anglani, Maria Giulia, Bussè, Cinzia, Mozzetta, Stefano, Gabelli, Carlo, Campi, Cristina, and Cecchin, Diego
- Subjects
- *
FRONTAL lobe diseases , *MENTAL illness , *FRONTOTEMPORAL dementia , *FRONTOTEMPORAL lobar degeneration , *MOTOR neurons ,BRAIN metabolism - Abstract
Late-onset primary psychiatric disease (PPD) and behavioral frontotemporal dementia (bvFTD) present with a similar frontal lobe syndrome. We compare brain glucose metabolism in bvFTD and late-onset PPD and investigate the metabolic correlates of cognitive and behavioral disturbances through FDG-PET/MRI. We studied 37 bvFTD and 20 late-onset PPD with a mean clinical follow-up of three years. At baseline evaluation, metabolism of the dorsolateral, ventrolateral, orbitofrontal regions and caudate could classify the patients with a diagnostic accuracy of 91% (95% CI: 0.81–0.98%). 45% of PPD showed low-grade hypometabolism in the anterior cingulate and/or parietal regions. Frontal lobe metabolism was normal in 32% of genetic bvFTD and bvFTD with motor neuron signs. Hypometabolism of the frontal and caudate regions could help in distinguishing bvFTD from PPD, except in cases with motor neuron signs and/or genetic bvFTD for which brain metabolism may be less informative. • Frontal lobe syndrome is shared by late-onset primary psychiatric disease and bvFTD. • Brain glucose metabolism may be mostly useful in the differential diagnosis. • Frontal cortex/caudate metabolism guided a correct classification in 91% of cases. • Sparing of frontal metabolism may be present in bvFTD with MND or genetic bvFTD. • Hypometabolism of parietal cortex may be present in psychiatric diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging.
- Author
-
Fraioli, Francesco, Albert, Nathalie, Boellaard, Ronald, Galazzo, Ilaria Boscolo, Brendel, Matthias, Buvat, Irene, Castellaro, Marco, Cecchin, Diego, Fernandez, Pablo Aguiar, Guedj, Eric, Hammers, Alexander, Kaplar, Zoltan, Morbelli, Silvia, Papp, Laszlo, Shi, Kuangyu, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Verger, Antoine, Van Weehaeghe, Donatienne, and Yakushev, Igor
- Subjects
- *
ARTIFICIAL intelligence , *BRAIN imaging , *DEEP learning , *ARTIFICIAL neural networks , *NUCLEAR medicine , *POSITRON emission tomography - Abstract
The article discusses the perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging. The authors highlight the potential of AI in advancing research and clinical practice in the field of molecular brain imaging. They emphasize the need for standardization of clinical brain image recording and imaging protocols, as well as the importance of annotated images and additional data for feeding AI algorithms. The article also explores the applications of AI in image acquisition, segmentation and registration, interpretability analysis, and specific clinical areas such as epilepsy, neurodegenerative and movement disorders, neuro-oncology, and psychiatric disorders. The authors acknowledge the challenges and limitations in implementing AI in these areas, including the need for large datasets, validation studies, and harmonization of AI algorithms. Overall, the article provides a comprehensive overview of the current state and future potential of AI in molecular brain imaging. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
15. Focal epilepsy followed by rapidly progressive frontotemporal dementia: a rare manifestation of <italic>VCP</italic> mutation.
- Author
-
Carlucci, Valentina, Salvalaggio, Alessandro, Riguzzi, Pietro, Fasolato, Davide, Bussè, Cinzia, Cecchin, Diego, and Cagnin, Annachiara
- Subjects
- *
PARTIAL epilepsy , *FRONTOTEMPORAL dementia , *EPILEPSY , *FRONTAL lobe diseases , *FRONTOTEMPORAL lobar degeneration , *NEUROLOGICAL disorders , *SYMPTOMS - Abstract
This document is a letter to the editor discussing a rare manifestation of a VCP mutation. The case report describes a 58-year-old woman who experienced focal epilepsy followed by rapidly progressive frontotemporal dementia. The woman had a family history of dementia and behavioral changes. Neurological examination revealed frontal lobe syndrome, and brain imaging showed frontal lobe atrophy and hypometabolism. Genetic testing confirmed a mutation in the VCP gene. The authors emphasize the importance of genetic testing and imaging in diagnosing neurological disorders and highlight the heterogeneity of VCP-related disorders. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
16. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
- Author
-
Piccardo, Arnoldo, Treglia, Giorgio, Fiz, Francesco, Bar-Sever, Zvi, Bottoni, Gianluca, Biassoni, Lorenzo, Borgwardt, Lise, de Keizer, Bart, Jehanno, Nina, Lopci, Egesta, Kurch, Lars, Massollo, Michela, Nadel, Helen, Roca Bielsa, Isabel, Shulkin, Barry, Vali, Reza, De Palma, Diego, Cecchin, Diego, Santos, Ana Isabel, and Zucchetta, Pietro
- Subjects
- *
POSITRON emission tomography , *NEUROBLASTOMA , *RADIONUCLIDE imaging , *SPATIAL resolution , *DOPA , *RADIOACTIVE tracers , *DATABASE searching - Abstract
Background: Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [123I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [123I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. Methods: We searched the PubMed database for studies performing a head-to-head comparison between [123I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([11C]C-HED), 18F-18F-3,4-dihydroxyphenylalanine ([18F]DOPA) [124I]mIBG and Meta-[18F]fluorobenzylguanidine ([18F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). Results: Ten studies were selected: two regarding [11C]C-HED, four [18F]DOPA, one [124I]mIBG, and three [18F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [18F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. Conclusions: PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. EANM position paper: theranostics in brain tumours—the present and the future.
- Author
-
Tolboom, Nelleke, Verger, Antoine, Albert, Nathalie L., Brendel, Matthias, Cecchin, Diego, Fernandez, Pablo Aguiar, Fraioli, Francesco, Guedj, Eric, Herrmann, Ken, Traub-Weidinger, Tatjana, Morbelli, Silvia, Yakushev, Igor, Zucchetta, Pietro, Barthel, Henryk, and Van Weehaeghe, Donatienne
- Subjects
- *
BRAIN tumors , *COMPANION diagnostics , *NEUROENDOCRINE tumors , *BLOOD-brain barrier , *DRUG target , *THYROID diseases - Abstract
The European Journal of Nuclear Medicine & Molecular Imaging has published a position paper on the use of theranostics in brain tumors. Theranostics, which involves using diagnostic imaging to identify specific molecular targets and then delivering targeted therapy, has shown promise in thyroid diseases, neuroendocrine tumors, and prostate cancer. The paper discusses the potential of theranostics in treating brain tumors, including meningiomas, gliomas, brain metastases, and pediatric brain tumors. It highlights the challenges in delivering therapeutics to the brain due to the blood-brain barrier and calls for further research and clinical trials to evaluate the efficacy of theranostic approaches in neuro-oncology. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
18. Minutes to hours after a nuclear event: available radiation poisoning antidotes and practical considerations on possible urgent approaches.
- Author
-
Taci, Xhoajda, Poletto, Giulia, Trotti, Flavio, Gramegna, Fabiana, Zorz, Alessandra, Giraudo, Chiara, Venturini, Francesca, Seno, Flavio, Realdon, Nicola, Vettor, Roberto, Faoro, Sonia, and Cecchin, Diego
- Subjects
- *
FUKUSHIMA Nuclear Accident, Fukushima, Japan, 2011 , *NUCLEAR accidents , *ANTIDOTES , *SCIENTIFIC literature , *POISONING , *IODINE radioisotopes , *IODINE isotopes - Abstract
A nuclear emergency is a type of accident that can expose a highly variable number of people to isotopes and radiation [[1]]. It can take time to identify radionuclides deposited in the environment and to measure the dose adsorbed by a given individual (which decides the need for specific treatments), but treatments must be started promptly to avoid target organ contamination and deposition. The radionuclides absorbed by the thyroid could lead to thyroid dysfunction and thyroid cancer. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
19. Prevalence of Incidental Findings Suspicious for Transthyretin Cardiac Amyloidosis among Patients Undergoing Bone Scintigraphy: A Systematic Review and a Meta-Analysis.
- Author
-
Treglia, Giorgio, Martinello, Chiara, Dondi, Francesco, Albano, Domenico, Bertagna, Francesco, Rizzo, Alessio, Delgado Bolton, Roberto C., Tersalvi, Gregorio, Muoio, Barbara, Riegger, Martin, and Cecchin, Diego
- Subjects
- *
CARDIAC amyloidosis , *TRANSTHYRETIN , *RADIONUCLIDE imaging , *NUCLEAR medicine , *BIBLIOGRAPHIC databases , *OLDER men - Abstract
Background: The myocardial uptake of bone-seeking tracers suspicious for transthyretin cardiac amyloidosis (ATTR-CA) can be incidentally detected in patients undergoing bone scintigraphy for noncardiac reasons. We conducted a systematic review and meta-analysis to assess the prevalence of these scintigraphic findings. Methods: A comprehensive literature search was performed using two bibliographic databases (PubMed/MEDLINE and Cochrane Library), searching for articles related to the review question. Eligible articles were selected, and relevant data were extracted by two authors. The pooled prevalence of incidental findings suspicious for ATTR-CA among patients undergoing bone scintigraphy was calculated on a per-patient-based analysis using a random-effects model. The pooled measure was provided with 95% confidence interval (95% CI) values. Results: Among 219 records, 11 articles were selected for the systematic review and 10 for the meta-analysis. The pooled prevalence of incidental findings suspicious for ATTR-CA was 1.1% (95% CI: 0.7–1.4%) with heterogeneity due to the characteristics of the included studies, patients, and index tests. These findings are more prevalent in older men. Conclusions: The prevalence of incidental findings of ATTR-CA among patients undergoing bone scintigraphy is low but not negligible. Nuclear medicine physicians should suggest, in the scintigraphic report, further clinical investigations when these findings are detected. Prospective studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
- Author
-
Fiorenzato, Eleonora, Biundo, Roberta, Cecchin, Diego, Frigo, Anna Chiara, Kim, Jinhee, Weis, Luca, Strafella, Antonio P., Antonini, Angelo, and Cagnin, Annachiara
- Subjects
- *
AMYLOID beta-protein , *ALZHEIMER'S disease diagnosis , *BRAIN imaging , *MILD cognitive impairment , *CEREBRAL amyloid angiopathy , *POSITRON emission tomography , *MONTREAL Cognitive Assessment , *COGNITION disorders - Abstract
Background: The pathological processes underlying cognitive impairment in Parkinson's disease (PD) are heterogeneous and the contribution of cerebral amyloid deposits is poorly defined, particularly in the early stages of the disease.Objective: To investigate regional [18F]florbetaben binding to amyloid-β (Aβ) and its contribution to cognitive dysfunction in early stage PD.Methods: A multicenter cohort of 48 PD patients from the Parkinson's Progression Marker Initiative (PPMI) underwent [18F]florbetaben positron emission tomography (PET) scanning. Clinical features, including demographic characteristics, motor severity, cerebrospinal fluid (CSF), and cognitive testing were systematically assessed according to the PPMI study protocol. For the purpose of this study, we analyzed various neuropsychological tests assessing all cognitive functions.Results: There were 10/48 (21%) amyloid positive PD patients (PDAβ+). Increased [18F]florbetaben uptake in widespread cortical and subcortical regions was associated with poorer performance on global cognition, as assessed by Montreal Cognitive Assessment (MoCA), and impaired performance on Symbol Digit Modality test (SDMT). Further, we found that PDAβ+ patients had higher CSF total-tau/Aβ1 - 42 (p = 0.001) and phosphorylated-tau/Aβ1 - 42 in (p = 0.002) compared to amyloid-negative PD.Conclusion: These findings suggest that multiple disease processes are associated with PD cognitive impairment and amyloid deposits may be observed already in early stages. However, prevalence of amyloid positivity is in the range of literature age-matched control population. Increased cortical and subcortical amyloid is associated with poor performance in attentive-executive domains while cognitive deficits at MoCA and SDMT may identify amyloid-related dysfunction in early PD. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Ankle and Foot: Focus on Inflammatory Disease.
- Author
-
Giraudo, Chiara, Fichera, Giulia, Ganguly, Sujata, Arumugam, Moorthy, Cecchin, Diego, and Rennie, Winston J.
- Subjects
- *
JUVENILE idiopathic arthritis , *ANKLE , *JOINTS (Anatomy) , *MAGNETIC resonance imaging , *SPONDYLOARTHROPATHIES , *INFECTIOUS arthritis - Abstract
The ankle and foot have numerous bones and complex joints that can be affected by several types of inflammatory arthritis with different patterns and various radiologic signs, depending on the phase of the disease. Involvement of these joints is most frequently seen in peripheral spondyloarthritis and rheumatoid arthritis in adults and juvenile idiopathic arthritis in children. Although radiographs are a mainstay in the diagnostic process, ultrasonography and especially magnetic resonance imaging allow early diagnosis and are crucial diagnostic tools. Some diseases have typical features based on target populations (e.g., adults versus children, men versus women), but others may have overlapping imaging characteristics. We highlight key diagnostic features and describe appropriate investigations to guide clinicians toward the correct diagnosis and provide support during disease monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. The dynamic functional connectivity fingerprint of high-grade gliomas.
- Author
-
Moretto, Manuela, Silvestri, Erica, Facchini, Silvia, Anglani, Mariagiulia, Cecchin, Diego, Corbetta, Maurizio, and Bertoldo, Alessandra
- Subjects
- *
FUNCTIONAL connectivity , *GLIOMAS , *HIDDEN Markov models , *BRAIN tumors , *HUMAN fingerprints - Abstract
Resting state fMRI has been used in many studies to investigate the impact of brain tumours on functional connectivity (FC). However, these studies have so far assumed that FC is stationary, disregarding the fact that the brain fluctuates over dynamic states. Here we utilised resting state fMRI data from 33 patients with high-grade gliomas and 33 healthy controls to examine the dynamic interplay between resting-state networks and to gain insights into the impact of brain tumours on functional dynamics. By employing Hidden Markov Models, we demonstrated that functional dynamics persist even in the presence of a high-grade glioma, and that patients exhibited a global decrease of connections strength, as well as of network segregation. Furthermore, through a multivariate analysis, we demonstrated that patients' cognitive scores are highly predictive of pathological dynamics, thus supporting our hypothesis that functional dynamics could serve as valuable biomarkers for better understanding the traits of high-grade gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Rectal cancer staging: An up-to-date pictorial review.
- Author
-
Crimì, Filippo, Lacognata, Carmelo, Cecchin, Diego, Zucchetta, Pietro, and Pomerri, Fabio
- Subjects
- *
RECTAL cancer , *POSITRON emission tomography , *MAGNETIC resonance imaging , *RADIOTHERAPY , *METASTASIS - Abstract
Colorectal cancer is the third most common malignancy worldwide, and rectal cancer (RC) accounts for 29% of all cases. Local staging of RC is crucial for the purposes of addressing patients appropriately to surgery alone or to preoperative chemoradiotherapy (pCRT) followed by total mesorectal excision (TME). Combined pCRT and TME may negatively affect rectal function, so rectum-sparing approaches such as transanal local excision have been proposed as an alternative to TME for patients showing a major or complete clinical response on restaging after pCRT. Magnetic resonance imaging (MRI) has a fundamental role in the local staging and restaging of RC, with or without positron emission tomography (PET). PET/MRI enables a multiplanar high-resolution morphological study of the pelvis, providing important information on cell density and metabolic activity with diffusion-weighted imaging (DWI) and 18 F fluorodeoxyglucose uptake respectively. This article offers a pictorial review of the MRI anatomy of the ano-rectal region and an update on local RC staging with a hybrid 18 F-FDG PET/MRI scan. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Frontotemporal dementia phenotype in late-onset Huntington disease without chorea.
- Author
-
Bonato, Giulia, Mozzetta, Stefano, Bussè, Cinzia, Cecchin, Diego, and Cagnin, Annachiara
- Subjects
- *
FRONTOTEMPORAL dementia , *HUNTINGTON disease , *MOVEMENT disorders , *ALZHEIMER'S disease , *SPINOCEREBELLAR ataxia , *CHOREA , *MILD cognitive impairment - Abstract
Although brain amyloidosis was detected with CSF biomarker, a diagnosis of co-morbid Alzheimer disease was excluded due to negative biomarkers of amyloid-related neurodegeneration. In fact, the diagnosis of probable bvFTD requires functional imaging in cases where brain CT/MRI does not reveal atrophic changes in frontal and/or temporal lobes [[7]]. 1[ 18 F]FDG-PET/MRI of the brain of the patient detailing mild hypometabolism in the bilateral fronto-mesial cortex and involvement of the caudate nucleus bilaterally, which appears hypometabolic compared to the putamen. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
25. [ 18 F]FDG PET-MR in the Evaluation and Follow-Up of Incidental Bone Ischemic Lesions in a Mono-Center Cohort of Pediatric Patients Affected by Hodgkin's Lymphoma.
- Author
-
Giraudo, Chiara, Carraro, Elisa, Cavallaro, Elena, Zuliani, Monica, Spampinato Gotsyak, Liliya, Massano, Davide, Modugno, Antonella, Mussolin, Lara, Biffi, Alessandra, Cecchin, Diego, Pillon, Marta, and Zucchetta, Pietro
- Subjects
- *
HODGKIN'S disease , *CHILD patients , *YOUNG adults , *ASYMPTOMATIC patients , *BLOOD flow - Abstract
Hodgkin's lymphoma (HL) is one of the neoplasms with the best prognosis in children, adolescents and young adults, but sufferers are burdened by the possibility of developing adverse effects such as Bone Ischemic Lesions (BILs) which are lesions of the bone caused by the loss of/reduction in blood flow. The main goal of this retrospective study was to evaluate the role of [18F]FDG-PET-MR in the early detection of BILs in a single-center cohort of uniformly treated pediatric HL patients. BILs were assessed through PET-MR images as the appearance of medullary lesion surrounded by a serpiginous, tortuous border. From 2017 to 2022, 10/53 (18.9%) HL patients developed BILs which were mostly (8/10 patients) multifocal. Overall, 30 lesions were identified in the 10 asymptomatic patients, all with the above-mentioned features at MR and with very low [18F]FDG uptake. BILs were incidentally detected during HL therapy (n = 6) and follow-up (n = 4), especially in the long bones (66.7%). No factors correlated with the occurrence of BIL were identified. No patients developed complications. PET-MR is a sensitive combined-imaging technique for detecting BILs that are asymptomatic and self-limiting micro-ischemic lesions. BILs can be monitored by clinical follow-up alone both during and after therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI.
- Author
-
Barilà, Gregorio, Crimì, Filippo, Arangio Febbo, Massimiliano, Pavan, Laura, Vedovato, Susanna, Cabrelle, Giulio, Zanon, Chiara, Campi, Cristina, Cecchin, Diego, Zucchetta, Pietro, Lacognata, Carmelo, Semenzato, Gianpietro, and Zambello, Renato
- Subjects
- *
MULTIPLE myeloma , *POSITRON emission tomography computed tomography , *MAGNETIC resonance imaging , *MONOCLONAL gammopathies , *PLASMACYTOMA - Abstract
Certainly, availability of PET/MRI device is limited to few centers, in addition, this imaging technique is burdened by longer imaging acquisition time and higher costs with respect to PET/CT or WB-DWI-MRI. Therefore, patients achieving both PET/CT and WB-DWI-MRI negativity after treatment showed improved PFS as compared to patients with residual disease by PET or MRI [[9]]. Regarding baseline PET/MRI evaluation, FLs were detected in 23 patients, with mean SUVmax of 4.4 ± 2.78 and mean ADC of 963 ± 264.6 mm SP 2 sp /s. At the end of treatment PET/MRI showed a PET negativity (DS <= 3) in 23/27 (85.2%) patients, a MRI negativity (RAC = 1) in 18/27 (66.7%) cases and a concomitant PET and MRI negativity (DS <= 3 and RAC = 1) in 18/27 (66.7%) cases. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
27. Assessment of structural disconnections in gliomas: comparison of indirect and direct approaches.
- Author
-
Silvestri, Erica, Villani, Umberto, Moretto, Manuela, Colpo, Maria, Salvalaggio, Alessandro, Anglani, Mariagiulia, Castellaro, Marco, Facchini, Silvia, Monai, Elena, D'Avella, Domenico, Della Puppa, Alessandro, Cecchin, Diego, Corbetta, Maurizio, and Bertoldo, Alessandra
- Subjects
- *
GLIOMAS , *BRAIN tumors , *DISEASE progression , *WHITE matter (Nerve tissue) , *STROKE , *DIFFUSION magnetic resonance imaging - Abstract
Gliomas are amongst the most common primary brain tumours in adults and are often associated with poor prognosis. Understanding the extent of white matter (WM) which is affected outside the tumoral lesion may be of paramount importance to explain cognitive deficits and the clinical progression of the disease. To this end, we explored both direct (i.e., tractography based) and indirect (i.e., atlas-based) approaches to quantifying WM structural disconnections in a cohort of 44 high- and low-grade glioma patients. While these methodologies have recently gained popularity in the context of stroke and other pathologies, to our knowledge, this is the first time they are applied in patients with brain tumours. More specifically, in this work, we present a quantitative comparison of the disconnection maps provided by the two methodologies by applying well-known metrics of spatial similarity, extension, and correlation. Given the important role the oedematous tissue plays in the physiopathology of tumours, we performed these analyses both by including and excluding it in the definition of the tumoral lesion. This was done to investigate possible differences determined by this choice. We found that direct and indirect approaches offer two distinct pictures of structural disconnections in patients affected by brain gliomas, presenting key differences in several regions of the brain. Following the outcomes of our analysis, we eventually discuss the strengths and pitfalls of these two approaches when applied in this critical field. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. A comparison of advanced semi-quantitative amyloid PET analysis methods.
- Author
-
Peira, Enrico, Poggiali, Davide, Pardini, Matteo, Barthel, Henryk, Sabri, Osama, Morbelli, Silvia, Cagnin, Annachiara, Chincarini, Andrea, and Cecchin, Diego
- Subjects
- *
AMYLOID , *EMISSION-computed tomography , *CLINICAL trials , *DATA analysis , *STATISTICAL correlation - Abstract
Purpose: To date, there is no consensus on how to semi-quantitatively assess brain amyloid PET. Some approaches use late acquisition alone (e.g., ELBA, based on radiomic features), others integrate the early scan (e.g., TDr, which targets the area of maximum perfusion) and structural imaging (e.g., WMR, that compares kinetic behaviour of white and grey matter, or SI based on the kinetic characteristics of the grey matter alone). In this study SUVr, ELBA, TDr, WMR, and SI were compared. The latter — the most complete one — provided the reference measure for amyloid burden allowing to assess the efficacy and feasibility in clinical setting of the other approaches. Methods: We used data from 85 patients (aged 44–87) who underwent dual time-point PET/MRI acquisitions. The correlations with SI were computed and the methods compared with the visual assessment. Assuming SUVr, ELBA, TDr, and WMR to be independent measures, we linearly combined them to obtain more robust indices. Finally, we investigated possible associations between each quantifier and age in amyloid-negative patients. Results: Each quantifier exhibited excellent agreement with visual assessment and strong correlation with SI (average AUC = 0.99, ρ = 0.91). Exceptions to this were observed for subcortical regions with ELBA and WMR (ρELBA = 0.44, ρWMR = 0.70). The linear combinations showed better performances than the individual methods. Significant associations were observed between TDr, WMR, SI, and age in amyloid-negative patients (p < 0.05). Conclusion: Among the other methods, TDr came closest to the reference with less implementation complexity. Moreover, this study suggests that combining independent approaches gives better results than the individual procedure, so efforts should focus on multi-classifier systems for amyloid PET. Finally, the ability of techniques integrating blood perfusion to depict age-related variations in amyloid load in amyloid-negative subjects demonstrates the goodness of the estimate. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Nanoparticles and Radioisotopes: A Long Story in a Nutshell.
- Author
-
Poletto, Giulia, Evangelista, Laura, Venturini, Francesca, Gramegna, Fabiana, Seno, Flavio, Moro, Stefano, Vettor, Roberto, Realdon, Nicola, and Cecchin, Diego
- Subjects
- *
SILICA nanoparticles , *GOLD nanoparticles , *RADIOISOTOPES , *NUCLEAR medicine , *NANOPARTICLES , *FERRIC oxide , *WEB databases , *IRON oxide nanoparticles - Abstract
The purpose of this narrative review was to assess the use of nanoparticles (NPs) to deliver radionuclides to targets, focusing on systems that have been tested in pre-clinical and, when available, clinical settings. A literature search was conducted in PubMed and Web of Science databases using the following terms: "radionuclides" AND "liposomes" or "PLGA nanoparticles" or "gold nanoparticles" or "iron oxide nanoparticles" or "silica nanoparticles" or "micelles" or "dendrimers". No filters were applied, apart from a minimum limit of 10 patients enrolled for clinical studies. Data from some significant studies from pre-clinical and clinical settings were retrieved, and we briefly describe the information available. All the selected seven classes of nanoparticles were highly tested in clinical trials, but they all present many drawbacks. Liposomes are the only ones that have been tested for clinical applications, though they have never been commercialized. In conclusion, the application of NPs for imaging has been the object of much interest over the years, albeit mainly in pre-clinical settings. Thus, we think that, based on the current state, radiolabeled NPs must be investigated longer before finding their place in nuclear medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. [18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases.
- Author
-
Evangelista, Laura, Crimì, Filippo, Visentin, Andrea, Voltan, Giacomo, Trentin, Livio, Lacognata, Carmelo, Cecchin, Diego, and Ceccato, Filippo
- Subjects
- *
LYMPHOMAS , *ADRENAL gland cancer , *COMPUTED tomography , *MAGNETIC resonance imaging , *METASTASIS - Abstract
Aim. The present study aimed to assess the existing data about Primary Adrenal Lymphoma (PAL) evaluated with FDG PET and to describe a small monocentric series of cases. A systematic analysis (from 2010 to 2022) was made by using PubMed and Web of Science databases reporting data about the role of FDG PET/CT in patients with suspicious or known adrenal lymphoma. The quality of the papers was assessed by using QUADAS-2 criteria. Moreover, from a single institutional collection between 2010 and 2021, data from patients affected by adrenal lymphoma and undergoing contrast-enhanced compute tomography (ceCT)/magnetic resonance (MR) and FDG PET/CT or PET/MR were retrieved and singularly described. Seventy-eight papers were available from PubMed and 25 from Web of Science. Forty-seven (Nr. 47) Patients were studied, most of them in the initial staging of disease (n = 42; 90%). Only in one paper, the scan was made before and after therapy. The selected clinical cases were relative to the initial staging of disease, the restaging, and the evaluation of response to therapy. PET/CT and PET/MR always showed a high FDG uptake in the primary adrenal lesions and in metastatic sites. Moreover, PET metrics, such as maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV), were elevated in all primary adrenal lesions. In conclusions, FDG PET either coupled with CT or MRI can be useful in staging, restaging, and for the evaluation of treatment response in patients affected by PAL [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee.
- Author
-
Verger, Antoine, Barthel, Henryk, Tolboom, Nelleke, Fraioli, Francesco, Cecchin, Diego, Albert, Nathalie L., van Berckel, Bart, Boellaard, Ronald, Brendel, Matthias, Ekmekcioglu, Ozgul, Semah, Franck, Traub-Weidinger, Tatjana, van de Weehaeghe, Donatienne, Morbelli, Silvia, and Guedj, Eric
- Subjects
- *
POST-acute COVID-19 syndrome , *SARS-CoV-2 , *POSITRON emission tomography , *COVID-19 , *SLEEP deprivation , *BRAIN imaging , *GRAY matter (Nerve tissue) - Abstract
Although the hypometabolic long COVID brain profile described above seems consistent with hypotheses and findings obtained for other viruses before the COVID-19 outbreak, with symptoms reported by patients with long COVID, and with results obtained from other diagnostic approaches assessing long COVID, the significance of these metabolic abnormalities in the individual patients remains to be determined. 2 Axial slices of a brain FDG PET scan of a patient with a hypometabolic long COVID pattern (A) and in a patient with a normal brain scan (B). Here, in 143 patients diagnosed in accordance with the current WHO definition of post-COVID syndrome, a hypometabolic long COVID pattern was observed in 47% of patients presenting persistent symptoms at an average of 10.9 months after COVID-19 [[28]]. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
32. Automatic assessment of body composition in children with lymphoma: results of a [18F]FDG-PET/MR study.
- Author
-
Giraudo, Chiara, Cavallin, Celeste, Pillon, Marta, Carraro, Elisa, Fichera, Giulia, Cecchin, Diego, and Zucchetta, Pietro
- Subjects
- *
BODY composition , *LOGISTIC regression analysis , *CHILD patients , *CHILDHOOD cancer , *LYMPHOMAS - Abstract
Objectives: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samples
t -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .Materials and methods: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samplest -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .Results: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samplest -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .Conclusions: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samplest -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .Clinical relevance statement: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samplest -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .Key Points: To use Dixon-MR images extracted from [18F]FDG-PET/MR scans to perform an automatic, volumetric segmentation and quantification of body composition in pediatric patients with lymphoma.Pediatric patients with lymphoma examined by [18F]FDG-PET/MR at diagnosis and restaging were included. At each time point, axial fat and water Dixon T1w images of the thighs were automatically segmented and muscle volume, subcutaneous, intramuscular, and intermuscular fat volume were quantified. The metabolic activity of the largest nodal lesion and of muscles and subcutaneous fat was recorded. The paired samplest -test and Spearman’s correlation coefficient were applied to evaluate potential differences between the two time points and the relationship between metabolic and body composition metrics, respectively. By logistic regression analysis, the prognostic role of the investigated variables was assessed. The applied significance level wasp < 0.05 for all analyses.Thirty-seven patients (mean age ± SD 14 ± 3-years-old; 20 females) matched the inclusion criteria. After chemotherapy (interval between the two PET/MR scans, 56–80 days; median 65 days), muscle volume significantly decreased (629 ± 259 cm3 vs 567 ± 243 cm3,p < 0.001) while subcutaneous, intramuscular and intermuscular fat increased (476 ± 255 cm3 vs 607 ± 254 cm3,p < 0.001; 63 ± 20 cm3 vs 76 ± 26 cm3,p < 0.001; 58 ± 19 cm3 vs 71 ± 23 cm3,p < 0.001); the metabolic activity of the main nodal lesion, muscles, and subcutaneous fat significantly decreased (p < 0.05, each). None of the examined variables acted as predictors of the response to treatment (p = 0.283). A strong correlation between BMI and subcutaneous fat volume at diagnosis (r = 0.675,p < 0.001) and restaging (r = 0.600,p < 0.001) emerged.The proposed method demonstrated that pediatric patients with lymphoma undergo muscle loss and an increase of subcutaneous fat during treatment.The proposed automatic and volumetric MR-based assessment of body composition in children with lymphoma can be used to monitor the effect of chemotherapy and may guide tailored exercise programs during chemotherapy.T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma .T1w Dixon images can be used for the automatic segmentation and quantification of body composition .Muscle and subcutaneous fat volume do not act as predictors of the response to treatment in children with lymphoma .Chemotherapy induces changes in body composition in children with lymphoma . [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
33. Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives.
- Author
-
Brendel, Matthias, Guedj, Eric, Yakushev, Igor, Morbelli, Silvia, Höglinger, Günter U., Tolboom, Nelleke, Verger, Antoine, Albert, Nathalie L., Cecchin, Diego, Fernandez, Pablo Aguiar, Fraioli, Francesco, Traub-Weidinger, Tatjana, Van Weehaeghe, Donatienne, and Barthel, Henryk
- Subjects
- *
LEWY body dementia , *PARKINSON'S disease , *DOPAMINERGIC imaging , *CARDIAC radionuclide imaging , *AUTOPSY , *BRAIN imaging , *POSITRON emission tomography - Abstract
The article focuses on advancing the biological definitions of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) through novel biomarker-driven frameworks like SyNeurGe and NSD-ISS, analogous to the ATN system in Alzheimer's disease. Topics include the integration of α-synucleinopathy detection using seed amplification assays in cerebrospinal fluid and skin, alongside neurodegeneration and dopaminergic deficit assessments via imaging biomarkers.
- Published
- 2024
- Full Text
- View/download PDF
34. FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective.
- Author
-
Verger, Antoine, Yakushev, Igor, Albert, Nathalie L., van Berckel, Bart, Brendel, Matthias, Cecchin, Diego, Fernandez, Pablo Aguiar, Fraioli, Francesco, Guedj, Eric, Morbelli, Silvia, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Van Weehaeghe, Donatienne, and Barthel, Henryk
- Subjects
- *
AMYLOID , *CLINICAL trials , *BIOMARKERS , *ALZHEIMER'S disease , *MILD cognitive impairment , *LECANEMAB - Abstract
The article focuses on the Food and Drug Administration approval of lecanemab an anti-Aβ drug for the treatment of Alzheimer's disease. Topics include the efficacy and consistent evidence of lecanemab in reducing amyloid burden and slowing cognitive decline, as well as the implications of its approval for the use of amyloid Positron emission tomography in Europe.
- Published
- 2023
- Full Text
- View/download PDF
35. Functional imaging by 11C-metomidate PET: a really useless technique for primary aldosteronism subtyping?
- Author
-
Crimì, Filippo, Spimpolo, Alessandro, Cecchin, Diego, and Rossi, Gian Paolo
- Subjects
- *
POSITRON emission tomography , *HYPERALDOSTERONISM , *ENDOCRINE diseases - Abstract
Secondly, although the radiotracer activity used by Soinio et al. was presumably similar to that used by O'Shea et al. and Burton et al., the PET images acquisition protocol differed markedly. Published by Bioscientifica Ltd. Printed in Great Britain © 2021 European Society of Endocrinology https://eje.bioscientifica.com https://doi.org/10.1530/EJE-20-1402 European Journal of Endocrinology 184:3 L9-L10 F Crimì and others Imaging by 11 C-metomidate PET Functional imaging by 11 C-metomidate PET: a really useless technique for primary aldosteronism subtyping?. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
36. Pelvic-ureteric junction obstruction and hypertension with target organ damage: A case report and review of the literature.
- Author
-
Pengo, Martino F., Soloni, Pietro, Cecchin, Diego, Maiolino, Giuseppe, Rossi, Gian Paolo, and Calò, Lorenzo A.
- Subjects
- *
TARGET organs (Anatomy) , *HYDRONEPHROSIS , *RENIN , *PATHOLOGICAL physiology - Abstract
Pelvic-ureteric junction obstruction (PUJO) is rare in adults and may be seen when the diagnosis has been missed in childhood. Hypertension may be a feature of PUJO but limited data are currently available in literature to support its association. We report a case of a 29-year-old woman who presented with severe hypertension. Work-up to exclude secondary hypertension showed high plasma renin activity, and imaging by ultrasound and computerized tomography a hydronephrosis and PUJO with impairment of kidney drainage at the renal scintigraphy. After double-J ureteric stenting, blood pressure decreased, antihypertensive medication tapered and the patients was normotensive with no antihypertensive medications after 6 months. We provide an update of the pathophysiology of hypertension in PUJO and a review of the available literature in order better to define the available treatments for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
37. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3.
- Author
-
Guedj, Eric, Varrone, Andrea, Boellaard, Ronald, Albert, Nathalie L., Barthel, Henryk, van Berckel, Bart, Brendel, Matthias, Cecchin, Diego, Ekmekcioglu, Ozgul, Garibotto, Valentina, Lammertsma, Adriaan A., Law, Ian, Peñuelas, Iván, Semah, Franck, Traub-Weidinger, Tatjana, van de Giessen, Elsmarieke, Van Weehaeghe, Donatienne, and Morbelli, Silvia
- Subjects
- *
BRAIN imaging , *CLINICAL indications , *NUCLEAR medicine , *NEURODEGENERATION , *HYPERGLYCEMIA , *GLUCOSE metabolism , *LYMPHOMA diagnosis , *DIAGNOSIS of dementia , *DIAGNOSIS of epilepsy , *ENCEPHALITIS diagnosis , *BRAIN , *MOVEMENT disorders , *MENTAL health , *GLIOMAS , *POSITRON emission tomography , *RADIOPHARMACEUTICALS , *PROFESSIONAL associations , *DEOXY sugars , *ONCOLOGY - Abstract
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction.
- Author
-
Lombardi, Giuseppe, Spimpolo, Alessandro, Berti, Sara, Campi, Cristina, Anglani, Maria Giulia, Simeone, Rossella, Evangelista, Laura, Causin, Francesco, Zorzi, Giovanni, Gorgoni, Giancarlo, Caccese, Mario, Padovan, Marta, Zagonel, Vittorina, and Cecchin, Diego
- Subjects
- *
DIFFUSION magnetic resonance imaging , *BIOMARKERS , *CHILD patients , *POSITRON emission tomography , *REGORAFENIB , *GLIOBLASTOMA multiforme , *OVERALL survival , *SURVIVAL analysis (Biometry) - Abstract
The use of regorafenib in recurrent glioblastoma patients has been recently approved by the Italian Medicines Agency (AIFA) and added to the National Comprehensive Cancer Network (NCCN) 2020 guidelines as a preferred regimen. Given its complex effects at the molecular level, the most appropriate imaging tools to assess early response to treatment is still a matter of debate. Diffusion-weighted imaging and O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography ([18F]FET PET) are promising methodologies providing additional information to the currently used RANO criteria. The aim of this study was to evaluate the variations in diffusion-weighted imaging/apparent diffusion coefficient (ADC) and [18F]FET PET-derived parameters in patients who underwent PET/MR at both baseline and after starting regorafenib. We retrospectively reviewed 16 consecutive GBM patients who underwent [18F]FET PET/MR before and after two cycles of regorafenib. Patients were sorted into stable (SD) or progressive disease (PD) categories in accordance with RANO criteria. We were also able to analyze four SD patients who underwent a third PET/MR after another four cycles of regorafenib. [18F]FET uptake greater than 1.6 times the mean background activity was used to define an area to be superimposed on an ADC map at baseline and after treatment. Several metrics were then derived and compared. Log-rank test was applied for overall survival analysis. Percentage difference in FET volumes correlates with the corresponding percentage difference in ADC (R = 0.54). Patients with a twofold increase in FET after regorafenib showed a significantly higher increase in ADC pathological volume than the remaining subjects (p = 0.0023). Kaplan–Meier analysis, performed to compare the performance in overall survival prediction, revealed that the percentage variations of FET- and ADC-derived metrics performed at least as well as RANO criteria (p = 0.02, p = 0.024 and p = 0.04 respectively) and in some cases even better. TBR Max and TBR mean are not able to accurately predict overall survival. In recurrent glioblastoma patients treated with regorafenib, [18F]FET and ADC metrics, are able to predict overall survival and being obtained from completely different measures as compared to RANO, could serve as semi-quantitative independent biomarkers of response to treatment. Simultaneous evaluation of [18F]FET and ADC metrics using PET/MR allows an early and reliable identification of response to treatment and predict overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Late-onset affective and psychotic disorders: The challenge of disentangling neurodegenerative diseases from primary psychiatric disorders.
- Author
-
Zorzi, Giovanni, Bussè, Cinzia, Cecchin, Diego, Roiter, Beatrice, Perini, Giulia, and Cagnin, Annachiara
- Subjects
- *
PSYCHOSES , *AFFECTIVE disorders , *MENTAL illness , *NEURODEGENERATION - Published
- 2021
- Full Text
- View/download PDF
40. The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community.
- Author
-
Garibotto, Valentina, Albert, Nathalie L., Barthel, Henryk, van Berckel, Bart, Boellaard, Ronald, Brendel, Matthias, Cecchin, Diego, Ekmekcioglu, Ozgul, van de Giessen, Elsmarieke, Guedj, Eric, Lammerstma, Adriaan A., Semah, Franck, Traub-Weidinger, Tatjana, Van Weehaeghe, Donatienne, and Morbelli, Silvia
- Subjects
- *
ALZHEIMER'S disease , *NUCLEAR medicine , *POSITRON emission tomography , *MEDICAL research , *PROGNOSIS - Abstract
The use of amyloid PET imaging as surrogate outcome measure of the effect of anti-AD drugs is a more complex matter and has been less explored. This article is part of the Topical Collection on Neurology On June 7th, 2021, for the first time since 2003, a novel drug against Alzheimer's disease (AD), aducanumab (Aduhelm™), has been approved in the USA by the Food and Drug Administration (FDA). We will focus here on two main aspects directly concerning our clinical and research practice: (1) using amyloid PET imaging as eligibility criterion and anticipating the associated needs, and (2) evaluating amyloid PET readout changes as surrogate outcome measures in clinical trials. SUVr is a biased measure for assessment of reduction of amyloid load after a pharmacotherapeutic intervention, as it shows a "reduction" in amyloid load over time in AD patients that in fact is an artefact linked with the perfusion reduction in cortical areas that occurs in AD patients over time [[24]]. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
41. Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer.
- Author
-
Evangelista, Laura, Cassarino, Gianluca, Lauro, Alberto, Morlacco, Alessandro, Sepulcri, Matteo, Nguyen, Alex Ahn Li, Ietto, Francesco, Cecchin, Diego, Lacognata, Carmelo, and Zucchetta, Pietro
- Subjects
- *
CHOLINE , *MAGNETIC resonance imaging , *RADICAL prostatectomy , *PROSTATE cancer , *NUCLEAR medicine , *ENDORECTAL ultrasonography , *PHYSICIANS - Abstract
Objectives: The aims of the study were (i) to examine the PCa detection rate of 18F-choline (FCH) PET/MRI and (ii) to assess the impact of PET/MRI findings in patients with PCa who develop OMD using PSA response as a biomarker. Methods: We retrospectively analyzed a cohort of 103 patients undergoing FCH PET/MRI for biochemical recurrence of PCa. The inclusion criteria were (1) previous radical prostatectomy (RP) with or without adjuvant radiotherapy (RT); (2) PSA levels available at the time of PET; (3) OMD, defined as a maximum of 5 lesions on PET/MRI; and (4) follow-up data available for at least 6 months after PET. All images were reviewed by two nuclear medicine physicians and interpreted with the support of two radiologists. Results: Seventy patients were eligible for the study: 52 patients had a positive FCH PET/MRI and 18 had a negative scan. The overall PCa detection rates for MRI, PET, and PET/MRI were 65.7%, 37.1%, and 74.3%, respectively. Thirty-five patients were treated with radiotherapy (RT), 16 received hormonal therapy (HT), 3 had a combined therapy (RT + HT), and 16 (23%) underwent PSA surveillance. At follow-up, PSA levels decreased in 51 patients (73%), most of whom had been treated with RT or RT + HT. Therapeutic management was guided by PET/MRI in 74% of patients, which performed better than MRI alone (68% of patients). Conclusion: FCH PET/MRI has a higher detection rate than MRI or PET alone for PCa patients with OMD and PSA levels > 0.5 ng/mL, prompting a better choice of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. The role of the deep convolutional neural network as an aid to interpreting brain [18F]DOPA PET/CT in the diagnosis of Parkinson's disease.
- Author
-
Piccardo, Arnoldo, Cappuccio, Roberto, Bottoni, Gianluca, Cecchin, Diego, Mazzella, Luca, Cirone, Alessio, Righi, Sergio, Ugolini, Martina, Bianchi, Pietro, Bertolaccini, Pietro, Lorenzini, Elena, Massollo, Michela, Castaldi, Antonio, Fiz, Francesco, Strada, Laura, Cistaro, Angelina, and Del Sette, Massimo
- Subjects
- *
CONVOLUTIONAL neural networks , *PARKINSON'S disease , *DOPA , *DIAGNOSIS , *COMPUTED tomography , *BRAIN imaging - Abstract
Objectives: To test the performance of a 3D convolutional neural network (CNN) in analysing brain [18F]DOPA PET/CT in order to identify patients with nigro-striatal neurodegeneration. We evaluated the robustness of the 3D CNN by testing it against a manual regional analysis of the striata by using a striatal-to-occipital ratio (SOR). Methods: We analyzed patients who had undergone [18F]DOPA PET/CT from 2016 to 2018. Two examiners interpreted PET/CT images as positive or negative. Only patients with at least 2 years of follow-up and an ascertained neurological diagnosis were included. A 3D CNN was developed to evaluate [18F]DOPA PET/CT and refine the diagnosis of movement disorder. This system required training and testing, which were carried out on 2/3 and 1/3 of patients, respectively. A regional analysis was also conducted by drawing region of interest on T1-weighted 3D MRI scans, on which the [18F]DOPA PET images were first co-registered. Results: Ninety-eight patients were enrolled: 43 presented nigro-striatal degeneration and 55 negative cases used as controls. After training on 69 patients, the diagnostic performance of the 3D CNN was then calculated in 29 patients. Sensitivity, specificity, negative predictive value, positive predictive value and accuracy were 100%, 89%, 100%, 85% and 93%, respectively. When we compared the 3D CNN results with the SOR analysis, we found that the two patients falsely classified as positive by the 3D CNN procedure showed SOR values ≤ 5th percentile of the negative cases' distribution. Conclusions: 3D CNNs are able to interpret [18F]DOPA PET/CT properly, revealing patients affected by Parkinson's disease. Key Points: •[18F]DOPA PET/CT is a sensitive diagnostic tool to identify patients with nigro-striatal neurodegeneration. • A semiquantitative evaluation of the images allows a more confident interpretation of the PET findings. • 3D convolutional neural network allows an accurate interpretation of 18F-DOPA PET/CT images, revealing patients affected by Parkinson's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. Complex oculomotor nerves palsy and incidental ischemic stroke as atypical presentation of giant cell arteritis.
- Author
-
Miscioscia, Alessandro, Decet, Paola, Angelini, Annalisa, Cecchin, Diego, and Cagnin, Annachiara
- Subjects
- *
GIANT cell arteritis , *OCULOMOTOR nerve , *ISCHEMIC stroke , *SYMPTOMS , *MULTINUCLEATED giant cells , *PARALYSIS - Abstract
28680132 5 Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. References 1 González-Gay MA, García-Porrúa C, Llorca J. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
44. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls.
- Author
-
Tiepolt, Solveig, Becker, Georg-Alexander, Wilke, Stephan, Cecchin, Diego, Rullmann, Michael, Meyer, Philipp M., Barthel, Henryk, Hesse, Swen, Patt, Marianne, Luthardt, Julia, Wagenknecht, Gudrun, Sattler, Bernhard, Deuther-Conrad, Winnie, Ludwig, Friedrich-Alexander, Fischer, Steffen, Gertz, Hermann-Josef, Smits, René, Hoepping, Alexander, Steinbach, Jörg, and Brust, Peter
- Subjects
- *
NICOTINIC acetylcholine receptors , *AMYLOID beta-protein , *ALZHEIMER'S disease , *POSITRON emission tomography , *BRAIN imaging , *ALZHEIMER'S patients - Abstract
Purposes: We present the first in-human brain PET imaging data of the new α4β2 nicotinic acetylcholine receptor (nAChR)–targeting radioligand (+)-[18F]Flubatine. Aims were to develop a kinetic modeling-based approach to quantify (+)-[18F]Flubatine and compare the data of healthy controls (HCs) and patients with Alzheimer's disease (AD); to investigate the partial volume effect (PVE) on regional (+)-[18F]Flubatine binding; and whether (+)-[18F]Flubatine binding and cognitive test data respective β-amyloid radiotracer accumulation were correlated. Methods: We examined 11 HCs and 9 mild AD patients. All subjects underwent neuropsychological testing and [11C]PiB PET/MRI examination. (+)-[18F]Flubatine PET data were evaluated using full kinetic modeling and regional as well as voxel-based analyses. Results: With 270-min p.i., the unchanged parent compound amounted to 97 ± 2%. Adequate fits of the time-activity curves were obtained with the 1 tissue compartment model (1TCM). (+)-[18F]Flubatine distribution volume (binding) was significantly reduced in bilateral mesial temporal cortex in AD patients compared with HCs (right 10.6 ± 1.1 vs 11.6 ± 1.4, p = 0.049; left 11.0 ± 1.1 vs 12.2 ± 1.8, p = 0.046; one-sided t tests each). PVE correction increased not only (+)-[18F]Flubatine binding of approximately 15% but also standard deviation of 0.4–70%. Cognitive test data and (+)-[18F]Flubatine binding were significantly correlated in the left anterior cingulate, right posterior cingulate, and right parietal cortex (r > 0.5, p < 0.05 each). In AD patients, (+)-[18F]Flubatine binding and [11C]PiB standardized uptake value ratios were negatively correlated in several regions; whereas in HCs, a positive correlation between cortical (+)-[18F]Flubatine binding and [11C]PiB accumulation in the white matter was found. No adverse event related to (+)-[18F]Flubatine occurred. Conclusion: (+)-[18F]Flubatine is a safe and stable PET ligand. Full kinetic modeling can be realized by 1TCM without metabolite correction. (+)-[18F]Flubatine binding affinity was high enough to detect group differences. Of interest, correlation between white matter β-amyloid PET uptake and (+)-[18F]Flubatine binding indicated an association between white matter integrity and availability of α4β2 nAChRs. Overall, (+)-[18F]Flubatine showed favorable characteristics and has therefore the potential to serve as α4β2 nAChR–targeting PET ligand in further clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. PET/MRI in prostate cancer: a systematic review and meta-analysis.
- Author
-
Evangelista, Laura, Zattoni, Fabio, Cassarino, Gianluca, Artioli, Paolo, Cecchin, Diego, dal Moro, Fabrizio, and Zucchetta, Pietro
- Subjects
- *
MAGNETIC resonance imaging , *META-analysis , *POSITRON emission tomography , *GLEASON grading system , *ENDORECTAL ultrasonography , *PROSTATE cancer , *PROSTATE cancer patients , *CONTINGENCY tables - Abstract
Aim: In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). Materials and methods: A literature search was conducted in three different databases. The terms used were "choline" or "prostate-specific membrane antigen - PSMA" AND "prostate cancer" or "prostate" AND "PET/MRI" or "PET MRI" or "PET-MRI" or "positron emission tomography/magnetic resonance imaging." All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. Results: Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). Conclusions: PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
- Author
-
Evangelista, Laura, Ravelli, Ilaria, Bignotto, Antonio, Cecchin, Diego, and Zucchetta, Pietro
- Subjects
- *
NEUROENDOCRINE tumors , *PEPTIDE receptors , *POSITRON emission tomography computed tomography , *MAGNETIC resonance imaging , *LUNG cancer , *PATIENT selection - Abstract
The aim of the present review was to assess the role of combined 18F-Fluorodeoxyglucose (F-18 FDG) and Ga-68 DOTA-peptides positron emission tomography (PET)-computed tomography (CT) in neuroendocrine tumors (NETs). We have searched MEDLINE databases, including PubMed and Scopus, for studies about the combined FDG and Ga-68 DOTA-peptides PET-CT or PET/Magnetic Resonance Imaging (MRI) in NETs in the last 15 years (from 2004 to November 2019). No limits were applied to the search strategy. Abstracts, reviews, letters to editors, and editorials were excluded. Seven studies met the inclusion criteria. In total 236 patients received both 68Ga-DOTA-peptides and F-18 FDG PET-CT for the characterization of NETs. In particular, 84 patients had a neuroendocrine lung tumor while the others mainly a gastroenteropancreatic NET. The combined use of F-18 FDG and Ga-68 DOTA-peptides (mainly TOC) PET studies provides complementary information regarding different biological characteristics of the lesions, thus enabling a more accurate selection of patients for targeted radionuclide therapy and a better stratification of the prognosis. Ga-68 DOTA-peptides and F-18 FDG PET should be considered complementary in patients with NETs. They should be both performed in the initial staging and during follow-up, with a specific selection of patients and in a multidisciplinary vision. • Ga-68 DOTA-peptides and F-18 FDG PET-CT should be both performed in patients with neuroendocrine tumors. • Ga-68 DOTA-peptides uptake is higher in low-grade NETs, while F-18 FDG PET-CT uptake is high in G2 and G3 NETs. • F-18 FDG should be performed in case of negative or slightly positive Ga-68 DOTA-peptides PET-CT for identification of dedifferentiation status. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. COVID-19 and the brain: impact on nuclear medicine in neurology.
- Author
-
Morbelli, Silvia, Ekmekcioglu, Ozgul, Barthel, Henryk, Albert, Nathalie L., Boellaard, Ronald, Cecchin, Diego, Guedj, Eric, Lammertsma, Adriaan A., Law, Ian, Penuelas, Ivan, Semah, Franck, Traub-Weidinger, Tatjana, van de Giessen, Elsmarieke, Varrone, Andrea, and Garibotto, Valentina
- Subjects
- *
COVID-19 , *NUCLEAR medicine , *MEDICAL care , *COVID-19 pandemic , *SARS-CoV-2 , *HEALTH services accessibility , *NEUROLOGIC manifestations of general diseases - Published
- 2020
- Full Text
- View/download PDF
48. Cognitive improvement after cranioplasty: A possible volume transmission-related effect.
- Author
-
Jelcic, Nela, Pellegrin, Serena, Cecchin, Diego, Puppa, Alessandro, and Cagnin, Annachiara
- Subjects
- *
TREPHINING , *CEREBRAL circulation - Abstract
A letter to the editor is presented in response to the article "Cognitive improvement after cranioplasty: A possible volume transmission-related effect," published in previous issue.
- Published
- 2013
- Full Text
- View/download PDF
49. Proven validity and management impact of amyloid imaging in Alzheimer's disease—repetita juvant.
- Author
-
Barthel, Henryk, Arbizu, Javier, Drzezga, Alexander, Garibotto, Valentina, Lammertsma, Adriaan A., Morbelli, Silvia, for the EANM Neuroimaging Committee, Albert, Nathalie, Boellaard, Ronald, Cecchin, Diego, Ekmekcioglu, Ozgul, Guedj, Eric, Law, Ian, Penuelas, Ivan, Semah, Franck, Traub-Weidinger, Tatjana, van de Giessen, Elsmarieke, and Varrone, Andrea
- Subjects
- *
ALZHEIMER'S disease , *NEUROFIBRILLARY tangles , *MOLECULAR pathology - Abstract
The authors propose to abandon amyloid imaging and they base this statement primarily on the fact that amyloid imaging is not able to provide the full histopathological picture of AD (amyloid plaques & tau aggregates & neurodegeneration). This presence (regardless of whether amyloid aggregates cause the disease) is what is visualized by amyloid imaging in vivo to support the clinical AD diagnosis, no more, no less. The presence of amyloid pathology clearly is diagnostic, as it is required for the current gold standard neuropathological diagnosis of AD, and amyloid imaging verifiably provides this information in vivo. For amyloid imaging, the development level for the respective recommendations which can be found in the joint publication by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association on the Appropriate Use Criteria for Amyloid PET [[13]] is relatively high (in relation to that of other imaging procedures). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
50. The role of radiological and hybrid imaging for muscle metastases: a systematic review.
- Author
-
Lupi, Amalia, Weber, Michael, Del Fiore, Paolo, Rastrelli, Marco, Guglielmi, Giuseppe, Stramare, Roberto, Quaia, Emilio, Cecchin, Diego, and Giraudo, Chiara
- Subjects
- *
POSITRON emission tomography , *META-analysis , *NUCLEAR medicine , *BONE metastasis , *EVIDENCE-based medicine , *ONLINE information services , *TORSO , *SYSTEMATIC reviews , *METASTASIS , *MAGNETIC resonance imaging , *CANCER of unknown primary origin , *LUNG tumors , *CANCER , *URINARY organs , *GASTROINTESTINAL tumors , *DIAGNOSTIC imaging , *MUSCLE tumors , *COMPUTED tomography , *MEDLINE - Abstract
Aim Of the Study: Skeletal muscle metastases (SMM) are a rare entity, mainly detected at autopsy. Nevertheless, radiological and nuclear medicine imaging can contribute to the diagnosis with a significant impact on the treatment and prognosis of neoplastic patients. This study aimed to systematically review the features of SMM at imaging considering the primary tumors and the sites of occurrence.Materials and Methods: We conducted a systematic search of three electronic database (i.e., PubMed, Science Direct, and Web of Science) up to May 2019, without any language or time interval restriction. Two reviewers performed the search and selection process, data extraction, and synthesis. We resolved disagreements by consensus and/or involving a third reviewer. The included studies have been classified according to the Oxford Centre for Evidence Based Medicine (CEBM) grading system.Results: Out of 8598 and 1077 articles respectively for radiological and hybrid imaging, 29 papers were included. According to CEBM, twelve were level 4. Computed tomography (CT) is mainly applied and, despite the existence of CT and magnetic resonance-based classifications, these are rarely used. Positron emission tomography/CT allowed the detection of small and subtle lesion also in the extremities. Muscles of the trunk were mostly affected and mainly respiratory tumors are associated with this type of metastatic spread.Conclusion: Radiological and hybrid imaging allow a precise characterization of SMM. However, a more systematic approach, including also the application of available classification systems, may increase the diagnostic accuracy for this rare type of metastases.Key Points: • Skeletal muscle metastases have heterogeneous characteristics at imaging but mostly abscess-like features and high metabolic activity are described. • Skeletal muscle metastases mainly affect the muscles of the trunk. • Pulmonary, urological, and gastrointestinal cancers are the most frequent cause of skeletal muscle metastases. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.